Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma

Shimada, Hideaki; Takeda, Akihiko; Arima, Miwako; Okazumi, Shinichi; Matsubara, Hisahiro; Nabeya, Yoshihiro; Funami, Yutaka; Hayashi, Hideki; Gunji, Yoshio; Suzuki, Takao; Kobayashi, Susumu; Ochiai, Takenori

doi:10.1002/1097-0142(20001015)89:8<1677::aid-cncr5>3.0.co;2-9

Cited by 96 publications

(62 citation statements)

References 30 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients with RCC displayed decreases in the titer of the autoantibody after tumor resection, as shown in studies of an anti-p53 Ab in esophageal squamous cell carcinoma (Shimada et al 2000 and colorectal adenocarcinoma (Takeda et al 2001a, b). This Wnding suggests that the titer of the anti-PHD3 autoantibody may reXect the volume of the disease.…”

Section: Discussionmentioning

confidence: 80%

“…Various autoantibodies against cancer-speciWc antigens have been investigated to verify their potential as serological tumor markers. Autoantibodies against p53, IMP, p62, Koc, c-myc, cyclin-B1, and survivin were reported to be useful for detection of malignant tumors of various origins such as those of the esophagus, colorectum, bladder, prostate, stomach, liver, pancreas, lung, breast, and ovary (Barua et al 2007;Larsson et al 2006;Nilsson et al 2001;Shimada et al 2000Shimada et al , 2002Suzuki et al 2004;Takeda et al 2001a, b;Tan andZhang 2008: Zhong et al 2008). In RCC, we previously reported that livin, a member of the inhibitor of apoptosis protein family, was recognized as a tumor-speciWc antigen in patients and anti-livin autoantibodies were detected in their sera (Kitamura et al 2007).…”

Section: Discussionmentioning

confidence: 99%

“…This Wnding suggests that the titer of the anti-PHD3 autoantibody may reXect the volume of the disease. In addition, Shimada et al (2000Shimada et al ( , 2002 reported that persistent seropositivity for an anti-p53 Ab was associated with future disease recurrence in patients with esophageal cancer, which might indicate small residual cancer after surgery. In this study, some patients with clinically organ-conWned disease still had high titers of the anti-PHD3 Ab after surgical resection, though the titers decreased.…”

Section: Discussionmentioning

confidence: 99%

“…For various other cancers, several autoantibodies against cancer-speciWc antigens have been investigated as serological tumor markers (Barua et al 2007;Larsson et al 2006;Nilsson et al 2001;Shimada et al 2000Shimada et al , 2002Suzuki et al 2004;Takeda et al 2001a, b;Tan and Zhang 2008;Zhong et al 2008). We previously reported that an autoantibody against a cancer-speciWc antigen could be detected in sera of patients with RCC (Kitamura et al 2007).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma

Tanaka

Kitamura

Torigoe

et al. 2010

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma

Tanaka

Kitamura

Torigoe

et al. 2010

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Overexpression of mutant p53 protein has been found to induce serum p53 IgG antibodies (s-p53-Abs) in patients with esophageal squamous cell carcinoma (SCC) [1,2] including stage I cancer [3]. Our previous report showed that monitoring s-p53-Abs was useful for predicting tumor recurrence in patients with esophageal SCC, possibly because the antibody response is caused by the presence of residual cancer cells [4].…”

Section: Introductionmentioning

confidence: 99%

Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case

et al. 2013

Self Cite

View full text Add to dashboard Cite

We monitored serum p53 antibody (s-p53-Ab) titers in a 76-year-old man with esophageal adenocarcinoma, clinical stage III (T2N2M0), for over 4 years, including during the perioperative period and throughout follow-up after surgery. Screening tests for CA19-9 (205 IU/ml) and s-p53-Abs (381 U/ml) were positive before treatment. After neoadjuvant chemotherapy with 5-FU and cisplatin, CA19-9 decreased to the normal range, but the s-p53-Ab titer remained positive (224 U/ml). Pathological findings of surgically resected specimens showed stage T1b disease and no lymph node metastases. After surgery, s-p53-Ab titers consistently decreased, with no disease recurrence. Although the s-p53-Ab titer remained positive even after 4 years, it decreased to 8.66, 3.59, 2.38, and 1.92 U/ml, 1, 2, 3, and 4 years after surgery, respectively. Thus, monitoring perioperative changes in s-p53-Ab titers proved useful for detecting the presence of residual cancer cells in a patient with superficial esophageal adenocarcinoma.

show abstract

p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma

Shimada

2018

Annals of Gastroent Surgery

Self Cite

View full text Add to dashboard Cite

We reviewed our research concerning p53 molecules in esophageal squamous cell carcinoma by focusing on the p53 molecular diagnosis and treatment of esophageal squamous cell carcinoma. First, we developed diagnostic tools to analyze serum p53 autoantibodies to detect esophageal squamous cell carcinoma. Positive rate was around 25% to 30% in all patients and around 20% even in stage I patients. Presence of serum p53 antibodies was significantly associated with overexpression of p53 protein in tumor cells. Seropositive patients were more likely than seronegative patients to be resistant to chemotherapy. Monitoring of the titer of serum p53 autoantibodies was useful in predicting patients at high risk of recurrence and/or treatment response. Second, using Ad5CMV‐p53 for 10 patients with advanced esophageal squamous cell carcinoma, we carried out a phase I/II study of adenoviral‐mediated p53 gene therapy. Although no complete response was observed, local tumor was stabilized in nine patients. No serious adverse events related to Ad5CMV‐p53 were observed in these patients. One patient survived for over 5 years after the start of p53 gene therapy. Intratumoral injection of Ad5CMV‐p53 is therefore safe, feasible, and biologically active when given in multiple doses to patients with esophageal squamous cell carcinoma. Our observations from these clinical studies indicate that p53 is a useful molecular target both in the diagnosis and in the treatment of esophageal squamous cell carcinoma.

show abstract

Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma

Cited by 96 publications

References 30 publications

Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma

Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma

Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case

p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma

Contact Info

Product

Resources

About